Risk Factors Update Summary

• Expansion of commercialization activities to Australia, New Zealand, South Korea, Southeast Asia, and Israel.
• The company faces increasing competition from generic drug companies, with several generic versions of VASCEPA launched, impacting revenues.
• Increased turnover among employees in Europe due to recent elimination of all sales force positions.
• The company initiated cost and organizational restructuring plans, reducing overall headcount by 30%.
• Legislative and enforcement interest in drug pricing practices may adversely affect demand and revenue potential.
• Net losses decreased from approximately $105.8 million in 2022 to $59.1 million in 2023.
• The company may not meet expectations for market acceptance of VASCEPA, especially with generic competition.
• The company may need to transition to new forms of transfer mechanisms for data transfers, impacting operations.
• Share repurchase program subject to shareholder and UK court approval, aiming to reduce shares outstanding.
• The company faces challenges in achieving market opportunities due to regulatory scrutiny and competition.
• The company may need to expand internally and manage additional relationships to support commercial growth.
• Legal, political, and economic uncertainties due to geopolitical tensions and armed conflicts impacting operations.
• Potential impact on sales, business, and financial condition due to changes in insurer policies regarding co-pay coupons.
• Uncertainty regarding the implementation of the share repurchase program and its impact on shareholder value.